

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 978 285 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

09.02.2000 Bulletin 2000/06

(51) Int. Cl.⁷: **A61K 38/17**

(21) Application number: 99115245.5

(22) Date of filing: 02.08.1999

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 07.08.1998 EP 98114851

03.09.1998 EP 98116734

(71) Applicant:

**F. HOFFMANN-LA ROCHE AG
4070 Basel (CH)**

(72) Inventor: **Papadimitriou, Apollon**

83673 Bichl (DE)

(74) Representative:

**Witte, Hubert, Dr. et al
124 Grenzacherstrasse
4070 Basel (CH)**

(54) **Pharmaceutical composition of hedgehog proteins and use thereof.**

(57) A composition of a hedgehog protein which contains as an additive zinc ions, magnesium ions, calcium ions, sulfate ions, cyclodextrin, a non-ionic detergent and/or an anionic saccharide is especially stable at room temperature.

EP 0 978 285 A1

Description

[0001] The invention concerns a composition, preferably a pharmaceutical composition, of hedgehog proteins and its use.

[0002] Hedgehog (hh) proteins are understood as a family of secreted signal proteins which are responsible for the formation of numerous structures in embryogenesis (J.C. Smith, *Cell* 76 (1994) 193 - 196, N. Perrimon, *Cell* 80 (1995) 517 - 520, C. Chiang et al., *Nature* 83 (1996) 407, M.J. Bitgood et al., *Curr. Biol.* 6 (1996) 298-304, A. Vortkamp et al., *Science* 273 (1996) 613, C.J. Lai et al., *Development* 121 (1995) 2349). During its biosynthesis a 20 kDa N-terminal domain and a 25 kDa C-terminal domain are obtained after cleavage of the signal sequence and autocatalytic cleavage. In its natural form the N-terminal domain is modified with cholesterol or palmitoyl (J.A. Porter et al., *Science* 274 (1996) 255 - 259, Pepinski et al., *J.Biol.Chem.* 273 (1998) 14037 - 14045). In higher life-forms the hh family is composed of at least three members namely sonic, indian and desert hh (shh, ihh, dhh; M. Fietz et al., *Development (Suppl.)* (1994) 43 - 51). Differences in the activity of hedgehog proteins that were produced recombinantly were observed after production in prokaryotes and eukaryotes (M. Hynes et al., *Neuron* 15 (1995) 35 - 44 and T. Nakamura et al., *Biochem. Biophys. Res. Comm.* 237 (1997) 465 - 469).

[0003] Hynes et al. compare the activity of hh in the supernatant of transformed human embryonic kidney 293 cells (eukaryotic hh) with hh produced from *E. coli* and find a four-fold higher activity of hh from the supernatants of the kidney cell line. The reason for this increased activity has been discussed to be a potential additional accessory factor which is only expressed in eukaryotic cells, a post-translational modification, a different N-terminus since the hh isolated from *E. coli* contains 50 % of a hh form which carries two additional N-terminal amino acids (Gly-Ser) or is shortened by 5 - 6 amino acids, or a higher state of aggregation (e.g. by binding to nickel agarose beads).

[0004] Nakamura et al. compare the activity of shh in the supernatant of transformed chicken embryo fibroblasts with an shh fusion protein isolated from *E. coli* which still has an N-terminal polyhistidine part. The shh in the supernatant of the fibroblasts has a seven-fold higher activity than the purified *E. coli* protein with regard to stimulation of alkaline phosphatase (AP) in C3H10T 1/2 cells. The increased activity has been postulated to be due to molecules such as for example bone morphogenetic proteins (BMPs) which are only present in the supernatant of eukaryotic cells and cause the stronger induction of AP.

[0005] Pepinski et al. (*J.Biol.Chem.* 273 (1998) 14037 - 14045) have identified a shh form which is modified with palmitic acid. This shh mutant is 30-fold more potent than the unmodified form in the C3H10T 1/2 assay.

[0006] Kinto et al., *FEBS Letters*, 404 (1997) 319 - 323 described that fibroblasts which secrete hh induce ectopic bone formation in an i.m. implantation on collagen. Thus hedgehog proteins have an osteoinductive activity. Hedgehog proteins can also stimulate the formation of cartilage cells (Stott et al., 1997).

[0007] It is known from Yang et al., *Development* 124 (1997) 4393-4404 that high local hedgehog concentrations must prevail over a period of at least 16 h at the site of action in the body for a pharmaceutically effective *in vivo* activity. The carrier system described by Yang et al. i.e. the hedgehog-loaded chromatography medium Affigel CM, the Ni agarose described by Marti et al., in *Nature* 375 (1995) 322-325 or the Affigel blue used by Lopez-Martinez et al., in *Curr.Biol.* 5 (1995) 791-796 or the heparin agarose particles that they used are less suitable for a pharmaceutical application since they are immunogenic and can cause inflammatory reactions.

[0008] The object of the invention is to provide a stable, preferably aqueous (preferably pharmaceutical) composition of a hedgehog protein.

[0009] The object is achieved by a, preferably pharmaceutical, composition of a hedgehog protein which contains a hedgehog protein in a pharmaceutically effective amount and, as an additive, zinc ions, magnesium ions, calcium ions, sulfate ions, cyclodextrin, non-ionic detergents and/or anionic saccharides such as chondroitin sulfate or heparin.

[0010] It has surprisingly turned out that one or several additives selected from the group zinc ions, magnesium ions, sulfate ions and cyclodextrin, non-ionic detergents, anionic saccharides such as chondroitin sulfate or heparin are able to stabilize hedgehog proteins (as a pharmaceutical composition or in another form), preferably in an aqueous solution. As a result the activity of the hedgehog protein can be maintained over a long period for example at room temperature and the compositions of hedgehog proteins can be stored for a long period at room temperature. The additives according to the invention are also suitable for stabilizing hedgehog lyophilisates (preferably as a bulk or pharmaceutical composition) and also stabilize the hedgehog proteins during the production of hedgehog preparations such as implants, microparticles, gels etc. and at increased temperatures (e.g. 37°C).

[0011] In the aqueous solution of the hedgehog protein according to the invention the additive is in a molar excess relative to the hedgehog proteins. This excess is preferably 1 - 1000-fold and particularly preferably 1 - 100-fold. The aqueous solution according to the invention is especially suitable for producing combinations of hedgehog proteins with carrier substances.

[0012] Hence a further subject matter of the invention is an aqueous solution of a hedgehog protein which is characterized in that it contains a molar excess of the additive according to the invention relative to the hedgehog protein. This solution is preferably buffered and/or lyophilized.

[0013] The amount of additives according to the invention is per se uncritical and can be varied over a wide range. Suitable amounts depend on the pharmaceutical compatibility of the additive and the extent of the stabilizing action at a pharmaceutically acceptable concentration. Zinc ions are particularly preferred as a stabilizer and can for example be advantageously added at a concentration of 0.01 - 100 mmol/l. This concentration has a significant stabilizing effect on hedgehog proteins. Zinc ions are preferably added at pharmaceutically compatible doses.

[0014] Cyclodextrin can be preferably present according to the invention as cyclodextrin sulfate. The concentrations are preferably between 1 and 20 % by weight. Low molecular weight heparin (ca. 3 kDa) is preferably used as an anionic polysaccharide. The concentration is preferably 0.5 - 50 mg/ml for low molecular weight heparin and corresponding molar amounts are used for high molecular weight heparin. Sulfate ions are preferably added as zinc sulfate. The sulfate ion concentration is preferably 0.01 - 100 mmol/l. Calcium and magnesium ions are preferably used at a concentration of 0.01 - 100 mmol/l. Non-ionic detergents are preferably polyoxysorbates (e.g. Tween®20, Tween®80), preferably at a concentration of 0.01 to 0.1% (w/v).

[0015] The hedgehog protein is preferably present on a biocompatible carrier in which case the carrier binds the hedgehog protein in its active, folded structure and can locally release hedgehog protein in vivo in its active form and in a delayed manner. Such formulations are particularly suitable for the repair of bone and cartilage defects, but can also be used to repair neuronal defects or for a systemic delivery.

[0016] In a preferred embodiment the composition, and preferably the pharmaceutical composition, contains the hedgehog protein bound to a hydrophilic carrier which is biocompatible and can for example be used as an implant. The carrier is preferably a polymer which

- binds the hedgehog protein as a negatively charged carrier as a result of ionic interactions,
- the hedgehog protein is not denatured when it is bound to the carrier,
- the carrier contains at least 0.1 to 1, preferably 0.1 to 2 negatively charged residues per monomer under neutral conditions,
- the charge is mediated in the form of acidic groups such as sulfate, carboxyl or phosphate groups,
- and the average molecular weight of the carrier is at least 50,000 Da.

[0017] It has turned out that hedgehog proteins can be reversibly and actively released in vivo from a carrier in a delayed manner when they are bound to a negatively charged, soluble or insoluble polymer matrix. Such carrier matrices are for example described in the European Patent Application No. 98104416.7.

[0018] A pharmaceutical effect is preferably understood as a neurological effect on nerve cells, a chondrogenesis and/or chondroinduction and preferably osteogenesis and/or osteoinduction as described in Kinto et al., FEBS Letters, 404 (1997) 319 - 323 for bone induction, by Miao et al. in J. Neurosci. 17 (1997) 5891-5899 for the effect on nerve cells and by Stott et al., in J. Cell Sci. 110 (1997) 2691-2701 for cartilage cell induction.

[0019] Solutions of hedgehog proteins at high concentrations are required to produce carrier matrices that are coated with hedgehog proteins in such a manner that they exhibit an adequate pharmaceutical efficacy when applied locally. It has turned out that pharmaceutically suitable carriers coated with hedgehog protein should preferably contain a concentration of the hedgehog protein of 0.1 - 10 mg/ml carrier and more. Carriers are particularly advantageous which contain hedgehog proteins at a concentration of 0.1 - 10 mg/ml carrier or more. Hedgehog proteins are inherently poorly soluble. It has, however, surprisingly turned out that the solubility of hedgehog proteins increases considerably, hedgehog proteins are protected from oxidation and the stability of hedgehog proteins is improved at low concentrations (1 mg/ml or less) in solutions which contain arginine or arginium ions (preferably arginium sulfate). A further subject matter of the invention is therefore aqueous solutions of hedgehog proteins according to the invention at a concentration of 1 mg/ml and more which additionally contain arginine or arginium ions and are preferably buffered. A further subject matter of the invention is a process for the production of a carrier matrix coated with hedgehog protein which is characterized in that the carrier matrix is incubated with a hedgehog protein solution according to the invention at a concentration of 1 - 10 mg/ml hedgehog protein which contains the additives according to the invention and arginine or arginium ions, preferably as arginium sulfate, and the carrier matrix coated in this manner is isolated.

[0020] Such solutions are suitable for producing carrier matrices which contain hedgehog proteins in pharmaceutically effective concentrations and are suitable for pharmaceutical applications. The concentration of arginine or arginium ions or arginium sulfate is preferably between 10 and 700 mmol/l, most preferably between 10 and 500 mmol/l, preferably in the pH range between 5 and 8, most preferably in the pH range between 6 and 8.

[0021] Activity within the sense of the invention is understood as the activity of alkaline phosphatase (stimulation of the expression of alkaline phosphatase) which the polypeptide can induce in mammalian cells (activity in the alkaline phosphatase test). In this method a mouse fibroblast cell line is cultured in a medium which contains foetal calf serum. Subsequently sterile filtered sample is added, the cells are lysed after ca. 5 days and alkaline phosphatase is determined in the cell lysate by means of the cleavage of a chromogenic substrate (pNP, p-nitrophenol) (J. Asahina, Exp. Cell. Res. 222 (1996) 38 - 47 and T. Nakamura (1997)).

[0022] A hedgehog protein is understood by the invention as a secreted signal protein which is responsible for the formation of numerous structures in embryogenesis. Sonic, indian or desert hh are particularly preferably used (Fietz M. et al., Development (Suppl.) (1994) 43-51). The processed form (N-terminal mature signal domain) of sonic hh protein (sequence: EMBL data bank, No. L38518) is preferably used. Proteins of the hedgehog family exhibit a pronounced homology in their amino acid sequence which is why it is also preferable to express those nucleic acids which code for hedgehog proteins which are 80 % or more homologous to the above-mentioned sequence of sonic hedgehog protein. Hedgehog derivatives are preferably used that are described for example in the European Patent Applications No. 98102095.1 and 98107911.4.

[0023] The human sonic hedgehog precursor protein is composed of the amino acids 1 - 462 of the sequence described in the EMBL databank under No. L38518. The amino acids 1 - 23 represent the signal peptide, the amino acids 24 - 197 represent the mature signal domain, the amino acids 32 - 197 represent the signal domain shortened by eight amino acids and the amino acids 198 - 462 represent the autoprocessed C-terminal domain after autoproteolytic cleavage.

[0024] The composition according to the invention contains a pharmacologically effective dose of the hh protein and can be administered locally or systemically. It is preferable to use the proteins according to the invention in combination with other proteins of the hedgehog family or bone growth factors such as bone morphogenetic proteins (BMPs) (Wozney et al., Cell.Mol.Biol. of Bone, Bone Morphogenetic Proteins and their Gene Expression (1993) Academic Press Inc., 131-167) or parathyroid hormones (Karablis et al., Genes and Development 8 (1994) 277-289) or insulin-like growth factors (IGF-I or II) or transforming growth factor family (TGF- β , GDFs).

[0025] The composition according to the invention preferably contains a polymer which essentially acts as the structural substance which preferably also has an adhesion function for cells. Collagen is for example such a structural substance. In this case it is preferable that the structural substance is present at a lower concentration than the hydrophilic biocompatible carrier described by the invention.

[0026] Furthermore it is preferable for the production of the composition to add auxiliary substances such as sugars (mannitol, sucrose, lactose, glucose, sucrose, trehalose, preferably 20-100 mg/ml) or amino acids such as glycine or arginine, methionine, cysteine as well as antioxidants such as citrate, thioglycerol, acetylcysteine, polyethylene glycol (1 - 10 % by weight), detergents, preferably non-ionic detergents (preferably 0.01 - 0.1 % by weight) such as polysorbates (Tween[®]20 or Tween[®]80) or polyoxyethylenes, anti-inflammatory agents, local anaesthetics, antibiotics and/or stabilizers such as lipids, fatty acids and glycerol.

[0027] In a further preferred embodiment a composition of the hedgehog protein according to the invention containing suramin is preferred and this can be used advantageously.

[0028] The composition can contain additional pharmaceutical auxiliary substances.

[0029] In a preferred embodiment the composition contains hedgehog protein at a concentration of 0.1 - 100 mg/ml.

[0030] In a preferred embodiment the composition additionally contains a pharmaceutically acceptable buffer which is biocompatible, preferably in the range between pH 3 and pH 10, particularly preferably in the range between pH 5 and 8. It has surprisingly turned out that the additives according to the invention are also able to effectively stabilize hedgehog proteins in the acidic range. The pH value of the composition should be advantageously greater than pH 4 in order to prevent denaturation and detachment of the zinc complexed in the hedgehog protein. The concentration of the buffer is preferably 1-500 mmol/l, in particular 5-150 mmol/l and particularly preferably 10-100 mmol/l. In the most preferred embodiments 300 mmol/l potassium phosphate buffer, pH 6.0 or 10 mmol/l potassium phosphate, 500 mmol/l arginine chloride, pH 6.0 is used.

[0031] The following examples and publications further elucidate the invention, the protective scope of which results from the patent claims. The described methods are to be understood as examples which still describe the subject matter of the invention even after modifications.

Example 1

DSC (differential scanning calorimetry) analysis of various hedgehog formulations

[0032] Hedgehog protein solutions with a protein concentration of ca. 0.5 mg/ml were analysed in various buffers (50 mM HEPES-NaOH, pH 7.2 and 150 mM arginine-Cl, pH 7.4) with or without stabilizers by means of DSC (Nano Differential Scanning Calorimeter, Calorimetry Sciences Corporation, Utah, USA) at a heating rate of 2 K/min. The following stabilizers were used:

- zinc acetate (Merck)
- zinc sulfate (Merck)
- heparin (low molecular weight, Sigma)
- sulfated β -cyclodextrin (Aldrich)

— arginine sulfate.

[0033] The transition temperatures (Tt) determined for the respective formulations are summarized in the table. It can be seen from the data shown that addition of the substances mentioned in the text increases the transition temperature and thus increases the stability of the hedgehog protein. The measured temperature values should not be understood as absolute values but rather represent differences in the stability of the individual formulations relative to one another.

[0034] Transition temperatures for hedgehog proteins in various formulations:

Formulations	Tt [°C]
50 mM Hepes-NaOH, pH 7.2	52.0
50 mM Hepes-NaOH, 1 mM zinc acetate, pH 7.2	56.8
50 mM Hepes-NaOH, 1 mM zinc sulfate, pH 7.2	60.6
150 mM arginine chloride, pH 7.4	53.5
150 mM arginine chloride, 5 % (w/v) sulfated β -cyclodextrin, pH 7.4	55.6
150 mM arginine chloride, 20 mg/ml heparin, pH 7.4	57.8
150 mM arginine sulfate, pH 6.0	63.4

Example 2

Stability of sonic hedgehog at 37°C

[0035] Human sonic hedgehog protein is incubated in various formulations at 37°C. Samples were taken at the stated times and analysed by means of rpHPLC.

Formulation A: PBS (10 mmol/l potassium phosphate, 150 mmol/l sodium chloride pH 7.4)

Time [h]	Recovery [%]	shh oxidized [%]	shh native [%]
0	100	-	78
1	104	-	44
5	173	-	68
24	134	71	29
48	140	76	24
72	142	84	16
96	39	79	21
168	31	79	21

Formulation B: 150 mM arginine-Cl, 0.01 % Tween 80, pH 6.0

Time [h]	Recovery [%]	shh oxidized [%]	shh native [%]
0	100	-	79
1	100	-	75

(continued)

Time [h]	Recovery [%]	shh oxidized [%]	shh native [%]
5	93	-	81
24	108	40	60
48	139	45	55
72	144	58	42
96	124	76	24
168	118	86	14

[0038] It is clear that hshh in formulation B is more stable than in formulation A. The oxidation of shh is considerably slower in the formulation containing arginine and the recovery is higher since the temperature-induced aggregation of hshh is prevented.

Example 3

Stability of hydrophobically modified shh at 37°C

[0039] Human hydrophobically modified sonic hedgehog protein (palmitoylated shh, prepared according to EP 98 116 733.1) is incubated in various formulations at 37°C. Samples are taken at various times and analysed by means of rpHPLC.

Formulation A: PBS (10 mmol/l potassium phosphate, 150 mmol/l sodium chloride, pH 7.4)

Time [h]	Recovery [%]	shh native [%]
0	100	91
1	81	80
5	-	84
24	74	70
48	25	47
72	31	40
96	4	0
168	4	0

Formulation B: 150 mM arginine-Cl, 0.01 % Tween 80, pH 6.0

Time [h]	Recovery [%]	shh native [%]
0	100	89
1	114	89
5	107	89
24	-	84
48	132	85
72	129	78

(continued)

Time [h]	Recovery [%]	shh native [%]
96	111	73
168	88	66

[0042] It is clear that hshh is more stable in formulation B than in formulation A. The recovery is higher since the temperature-induced aggregation of hshh is prevented.

List of References

[0043]

- Asahina, J., Exp. Cell. Res. 222 (1996) 38-47
 Bitgood, M.J. et al., Curr. Biol. 6 (1996) 298-304
 Chiang, C. et al., Nature 339 (1996) 407
 European Patent Application No. 98102095.1
 European Patent Application No. 98107911.4
 Fietz, M. et al., Development (Suppl) (1994) 43-51
 Hynes, M. et al., Neuron 15 (1995) 35-44
 Karablis et al., Genes and Development 8 (1994) 277-289
 Kinto et al., FEBS Letters, 404 (1997) 319-323
 Lai, C.J. et al., Development 121 (1995) 2349
 Lopez-Martinez et al. in Curr.Biol. 5 (1995) 791-796
 Marti et al., Nature 375 (1995) 322-325
 Miao et al., J. Neurosci. 17 (1997) 5891-5899
 Nakamura, T. et al., Biochem. Biophys. Res. Comm. 237 (1997) 465-469
 Pepinski et al., J.Biol.Chem. 273 (1998) 14037-14045
 Perrimon, N., Cell 80 (1995) 517-520
 Porter, J.A. et al., Science 274 (1996) 255-259
 Smith, J.C., Cell 76 (1994) 193-196
 Stott et al., J. Cell Sci. 110 (1997) 2691-2701
 Vortkamp, A. et al., Science 273 (1996) 613
 Wozney et al., Cell. Mol. Biol. of Bone, Bone Morphogenetic Proteins and their Gene Expression, (1993) Academic Press Inc. 131-167
 Yang et al., Development 124 (1997) 4393-4404

Claims

- Composition of a hedgehog protein which contains a hedgehog protein in a pharmaceutically effective amount and, as an additive, zinc ions, sulfate ions, magnesium ions, calcium ions, arginine or argininium ions, cyclodextrin, non-ionic detergent and/or an anionic saccharide.
- Composition as claimed in claim 1, wherein this composition contains zinc sulfate.
- Composition as claimed in claim 1, wherein this composition contains cyclodextrin sulfate.
- Composition as claimed in claim 1, wherein this composition contains arginine or argininium ions.
- Composition as claimed in claim 4, wherein this composition contains argininium sulfate.
- Composition as claimed in claim 1 or 2, wherein this composition contains zinc ions at a concentration of 0.01 - 100 mmol/l.
- Composition as claimed in claims 1 to 6, wherein the hedgehog protein is bound to a hydrophilic carrier which is biocompatible.

8. Composition as claimed in claims 1 to 7, wherein the hydrophilic carrier is a polymer.
9. Composition as claimed in claims 1 to 8, wherein the pharmaceutical composition contains a hedgehog protein at a concentration of 0.1 - 100 mg/ml.
10. Composition as claimed in claims 1 to 9, wherein the composition is buffered in a range between pH 3 and 10.
11. Composition as claimed in claims 1 to 10, wherein the hedgehog protein is bound to a biocompatible carrier.
12. Process for the production of a composition which contains a hedgehog protein, wherein a hedgehog protein in a pharmaceutical amount as well as zinc ions, magnesium ions, calcium ions, sulfate ions, cyclodextrin, non-ionic detergent, argininium, argininium ions and/or an anionic saccharide as an additive are used as essential components of this agent.
13. Process as claimed in claim 12, wherein a hedgehog protein at a concentration of 0.1 - 100 mg/ml is used.
14. Process for the delayed release of a hedgehog protein in the human body, wherein the hedgehog protein is administered locally in the human body in a pharmaceutically acceptable composition as claimed in claims 1 to 11.
15. Process as claimed in claim 14, wherein the hedgehog protein is administered at a concentration of 0.1 - 100 mg/ml.
16. Aqueous composition of a hedgehog protein, wherein this composition contains one or several additives selected from the group zinc ions, magnesium ions, calcium ions, sulfate ions, cyclodextrin, non-ionic detergent, argininium, argininium ions or an anionic saccharide in a molar excess relative to the hedgehog protein.
17. Lyophilisate of a composition as claimed in claims 1 to 11 or of an aqueous composition as claimed in claim 16.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 11 5245

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 98 30234 A (AIKAWA TOMONAO ; IWAMOTO MASAHIRO (JP)) 16 July 1998 (1998-07-16) * page 6 - page 7 *	1, 8, 11, 12	A61K38/17
Y, D	LOPEZ-MARTINEZ A ET AL: "LIMB-PATTERNING ACTIVITY AND RESTRICTED POSTERIOR LOCALIZATION OF THE AMINO-TERMINAL PRODUCT OF SONIC HEDGEHOG CLEAVAGE" CURRENT BIOLOGY, vol. 5, no. 7, 1 July 1995 (1995-07-01), pages 791-796, XP002072811 * page 796, paragraph 6 *	1	
Y	WO 95 23223 A (UNIV COLUMBIA ; JESSELL THOMAS M (US); DODD JANE (US); ROELINK HENK) 31 August 1995 (1995-08-31) * page 62 - page 65 *	1	
E	EP 0 947 201 A (ROCHE DIAGNOSTICS GMBH HRB 396) 6 October 1999 (1999-10-06) * paragraph '0011! * * paragraph '0016! * * paragraph '0020! * * paragraph '0021! * * paragraph '0027! * * paragraph '0029! * * paragraph '0032! * * paragraph '0033! *	1, 4, 5, 7-17	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K C07K
E	EP 0 953 575 A (ROCHE DIAGNOSTICS GMBH) 3 November 1999 (1999-11-03) * paragraph '0013! * * paragraph '0023! * * paragraph '0029! * * paragraph '0030! * * paragraph '0031! * * paragraph '0036! *	1, 4, 7-16	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 17 November 1999	Examiner Fernandez y Branas, F
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.02 (P4/C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 11 5245

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
E	EP 0 953 576 A (ROCHE DIAGNOSTICS GMBH) 3 November 1999 (1999-11-03) * paragraph '0010! * * paragraph '0013! * * paragraph '0038! * * paragraph '0044! * * paragraph '0045! * * paragraph '0046! * * paragraph '0049! * * paragraph '0052! *	1,4,7-17	
A	WO 95 18856 A (HARVARD COLLEGE ;IMP CANCER RES TECH (GB)) 13 July 1995 (1995-07-13) * page 62, line 23 - page 63, line 36; claim 46 *	1-17	
A	Hall, T.M.T. et al, "1VHH, Signalling Protein", 3-10-1995 Available from Internet: <URL: http://www.pdb.bnl.gov/pdb-bin/pdbids?id=1vhh> 5-01-1999 *whole document* XP002089253	1-17	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Place of search THE HAGUE		Date of completion of the search 17 November 1999	Examiner Fernandez y Branas, F
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (P4C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 11 5245

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

17-11-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9830234 A	16-07-1998	JP 10194987 A	28-07-1998
		AU 5495598 A	03-08-1998
WO 9523223 A	31-08-1995	AU 706024 B	03-06-1999
		AU 1930995 A	11-09-1995
		AU 2371899 A	17-06-1999
		CA 2184092 A	31-08-1995
		EP 0773995 A	21-05-1997
		JP 9509574 T	30-09-1997
EP 0947201 A	06-10-1999	AU 1542699 A	26-08-1999
		CZ 9900337 A	11-08-1999
		HR 990036 A	31-08-1999
		HU 9900251 A	28-09-1999
		NO 990471 A	05-08-1999
		PL 331201 A	16-08-1999
EP 0953575 A	03-11-1999	EP 0953576 A	03-11-1999
EP 0953576 A	03-11-1999	EP 0953575 A	03-11-1999
WO 9518856 A	13-07-1995	US 5789543 A	04-08-1998
		US 5844079 A	01-12-1998
		AU 704178 B	15-04-1999
		AU 1520795 A	01-08-1995
		AU 1645199 A	27-05-1999
		CA 2179029 A	13-07-1995
		EP 0741783 A	13-11-1996
		JP 9507853 T	12-08-1997
		NZ 278765 A	27-05-1998

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

